Loading…
Protecting Consumer Access to Generic Drugs Act of 2012
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
43pct
7d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (12)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2012 · fourth_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs, H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies, H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements, S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements, S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies, S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices, S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Copyright/Patent/Trademark
"S. 27 -- Preserve Access to Affordable Generics Act (entire bill)* "H.R. 2276, study on genetic testing (entire bill)* "S. 968, PROTECT IP Act (entire bill)* "H.R.3261, Stop Online Piracy Act (SOPA)* S.2029, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill)* H.R. 3782, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill)* S. 978, regarding penalties for copyright infringement (entire bill)* H.R. 2511, Innovative Design Protection and Piracy Prevention Act (entire bill)* S. 3523, Innovative Design Protection Act of 2012* S. 1228, Combating Military Counterfeits Act of 2011 (entire bill)* H.R. 2933, Sound Recording Simplification Act.(entire bill)* S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill)* H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill)* H.R. 3889, the PARTS Act (entire bill)* H.R. 3995, Protecting Consumer Access to Generic Drugs Act (entire bill)* H.R. 4216, the Foreign Counterfeit Prevention Act (entire bill) H.R. 6432, Patent Law Treaties Implementation Act of 2012 (entire bill) S. 3486, Patent Law Treaties Implementation Act of 2012 (entire bill) S. 3389, Protecting American Trade Secrets and Innovation Act of 2012 (entire bill) H.R. 6245, Saving High-Tech Innovators from Egregious Legal Disputes (SHIELD) Act (entire bill)* H.R. 6029, Foreign Economic Espionage Penalty Enhancement Act H.R. 6621, To correct certain provisions of the Leahy-Smith America Invents Act and title 35, United States Code (entire bill) S. 3642, Theft of Trade Secrets Clarification Act of 2012 (entire bill) H.R. 6654, Foreign Counterfeit Merchandise Prevention Act (entire bill) S. 3652, Patents for Humanity Program Improvement Act of 2012 (entire bill)
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · fourth_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs 16. Specific Lobbying Issues (continued): H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,020,000 · Firm income: Not reported
2012 · fourth_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements H.R. 4216, Foreign Counterfeit Protection Act: Provisions related to anti-counterfeiting H.R. 6502, Life-Threatening Diseases Compassion through Combination Therapy Act: Provisions related to market exclusivity and expedited review H.R. 6621, a bill to make technical corrections to the America Invents Act H.R. 6654, Foreign Counterfeit Merchandise Prevention Act: Provisions related to trade enforcement S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties S. 3652, Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates International intellectual property issues Biopharmaceutical innovation policy issues
2012 · fourth_quarter · Copyright/Patent/Trademark
H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs, provisions relating to authorized generics H.R. 3995 - Protect Consumer Access to Generic Drugs Act, provisions related to patent settlements H.R. 6621 - A bill to make technical corrections to the America Invents Act S. 27 - Preserve Access to Affordable Generics Act, provisions related to patent settlements S. 373 - The Fair Prescription Drug Competition Act, provisions related to authorized generics S. 1882 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $1,370,000 · Firm income: Not reported
| Democratic |
| NC |
| Henry A. Waxman | Democratic | CA |
| Janice D. Schakowsky | Democratic | IL |
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office
Client expense: $4,120,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Copyright/Patent/Trademark
Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R. 3497 - MODDERN Cures Act of 2011 H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R. 4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 S. 27 Preserve Access to Affordable Generics Act S. 373 Fair Prescription Drug Competition Act S. 1734 - Generating Antibiotic Incentives Now Act of 2011 S. 1882 - The Fair and Immediate Release of Generic Drugs Act S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act
Client expense: $486,262 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Pharmacy
FY 2014 Budget, FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R. 3839 - Drug Shortage Prevention Act of 2012 H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R. 4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R.6160 - Stop Tampering of Prescription Pills Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 H.R.6584 - Verifying Authority and Legality In Drug Compounding Act of 2012 H.R.6611 - Patient Access to Drugs in Shortage Act of 2012 H.R.6638 - S.A.F.E. Compounded Drugs Act of 2012 S. 44 Medicare Prescription Drug Negotiation Act S. 296 and H.R.2245 Preserving Access to Life-Saving Medication Act S. 373 Fair Prescription Drug Competition Act S. 1584 - Drug Safety and Accountability Act of 2011 S. 1734 - Generating Antibiotic Incentives Now Act of 2011 S. 2295 - Patient Safety and Generic Labeling Improvement Act S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Client expense: $486,262 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Copyright/Patent/Trademark
Opposed efforts to preclude settlements in patent litigation. H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012 S. 27, Preserve Access to Affordable Generics Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) S. 3389 (Trade Secrets EEA) S. 3486 (Patent Law Treaties Implementation Act of 2012) S. 3609 (Internet Radio Fairness Act) S. 3642 (Theft of Trade Secrets Clarification Act) S. 3652 (Bill to allow acceleration certificates awarded under the Patents for Humanity program to be transferable) S. Con. Res 50 (Internet governance) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 592 (Sunshine in Litigation Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3261 (Stop Online Piracy Act) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H.R. 6012 (Customs Redaction Bill for Semiconductor Chips) H.R. 6029 (Economic Espionage) H.R. 6215 (Trademark Dilution) H.R. 6245 (Saving High-Tech Innovators from Egregious Legal Disputes Act) H.R. 6353 (Patent Box, Manufacturing American Innovation Act) H.R. 6432 (Patent Law Treaties Implementation Act) H.R. 6480 (Internet Radio Fairness Act) H.R. 6621 (AIA Technical Corrections Bill) H. Con. Res. 42 (The Creativity and Innovation Resolution) H. Con. Res. 127 (Internet Governance)
Client expense: $60,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · fourth_quarter · Copyright/Patent/Trademark
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Copyright/Patent/Trademark
Opposed efforts to preclude settlements in patent litigation. H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012 S. 27, Preserve Access to Affordable Generics Act
Client expense: Not reported · Firm income: $9,000
Government targets: SENATE
2012 · third_quarter · Pharmacy
FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R. 3839 - Drug Shortage Prevention Act of 2012 H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R. 4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 H.R.6160 - Stop Tampering of Prescription Pills Act of 2012 H.R. 6433 - FDA User Fee Corrections Act of 2012 S. 44 Medicare Prescription Drug Negotiation Act S. 296 and H.R.2245 Preserving Access to Life-Saving Medication Act S. 373 Fair Prescription Drug Competition Act S. 1584 - Drug Safety and Accountability Act of 2011 S. 1734 - Generating Antibiotic Incentives Now Act of 2011 S. 2295 - Patient Safety and Generic Labeling Improvement Act S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
Client expense: $487,850 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Copyright/Patent/Trademark
Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs H.R. 2182 Generating Antibiotic Incentives Now Act of 2011 H.R. 3497 - MODDERN Cures Act of 2011 H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R. 4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 S. 27 Preserve Access to Affordable Generics Act S. 373 Fair Prescription Drug Competition Act S. 1734 - Generating Antibiotic Incentives Now Act of 2011 S. 1882 - The Fair and Immediate Release of Generic Drugs Act S. 2516 - Food and Drug Administration Safety and Innovation Act S. 3187 Food and Drug Administration Safety and Innovation Act
Client expense: $487,850 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Copyright/Patent/Trademark
"S. 27 -- Preserve Access to Affordable Generics Act (entire bill)* "H.R. 2276, study on genetic testing (entire bill)* "S. 968, PROTECT IP Act (entire bill)* "H.R.3261, Stop Online Piracy Act (SOPA)* S.2029, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill)* H.R. 3782, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill)* S. 978, regarding penalties for copyright infringement (entire bill)* S. 623, Sunshine in Litigation Act (entire bill)* H.R. 966, Lawsuit Abuse Reduction Act (entire bill)* S. 533, Lawsuit Abuse Reduction Act (entire bill)* H.R. 2511, Innovative Design Protection and Piracy Prevention Act (entire bill) S. 3523, Innovative Design Protection Act of 2012 S. 1228, Combating Military Counterfeits Act of 2011 (entire bill)* H.R. 2933, Sound Recording Simplification Act.(entire bill)* S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill)* H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill)* H.R. 3889, the PARTS Act (entire bill) H.R. 3995, Protecting Consumer Access to Generic Drugs Act (entire bill)* H.R. 4216, the Foreign Counterfeit Prevention Act (entire bill) H.R.5326, the Commerce, Justice, Science, and Related Agencies Appropriations Act, (PTO-related Provisions) S. 2323, the Commerce, Justice, Science, and Related Agencies Appropriations Act, (PTO-related Provisions) H.J. Res 117, Continuing Appropriations Act (PTO-related provisions) Issues related to ICANN and new gltds H.R. 6215 related to the Trademark Dilution Act (entire bill) H.R. 6432, Patent Law Treaties Implementation Act of 2012 (entire bill) S. 3486, Patent Law Treaties Implementation Act of 2012 (entire bill) S. 3389, Protecting American Trade Secrets and Innovation Act of 2012 (entire bill) H.R. 4078, the Red Tape Reduction and Small Business Creation Act (PTO-related amendment) H.R. 6245, Saving High-Tech Innovators from Egregious Legal Disputes (SHIELD) Act (entire bill)
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · third_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies. H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements. S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements. S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies. S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices. S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates [no bill number] Technical changes to America Invents Act [H.R. 1249 and S.23] International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs 16. Specific Lobbying Issues (continued): H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,630,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office
2012 · third_quarter · Copyright/Patent/Trademark
S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements H.R. 3995 - Protect Consumer Access to Generic Drugs Act - provisions related to patent settlements HR 3497 - MODERN Cures Act of 2011 - provisions related to data protection S.27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics H.R. 2182, S.1734 - Generating Antibiotic Incentives Now Act of 2011 - implementation of provisions related to antibiotics and incentives S.373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S. 1882 - The Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements No bill # assigned - International intellectual property issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Technical corrections to the America Invents Act
Client expense: $890,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2012 · third_quarter · Copyright/Patent/Trademark
Opposed efforts to preclude settlements in patent litigation. H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012 S. 27, Preserve Access to Affordable Generics Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) S. 3389 (Trade Secrets EEA) S. 3486 (Patent Law Treaties Implementation Act of 2012) S. Con. Res 50 (Internet governance) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H.R. 6012 (Customs Redaction Bill for Semiconductor Chips) H.R. 6029 (Economic Espionage) H.R. 6215 (Trademark Dilution) H.R. 6245 (Saving High-Tech Innovators from Egregious Legal Disputes Act) H.R. 6353 (Patent Box, Manufacturing American Innovation Act) H. Con. Res. 42 (The Creativity and Innovation Resolution) H. Con. Res. 127 (Internet Governance)
Client expense: $80,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · third_quarter · Copyright/Patent/Trademark
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: Not reported · Firm income: $36,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Copyright/Patent/Trademark
S. 27 -- Preserve Access to Affordable Generics Act (entire bill) H.R. 2276, study on genetic testing (entire bill) S. 968, PROTECT IP Act (entire bill) H.R.3261, Stop Online Piracy Act (SOPA) S.2029, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill) H.R. 3782, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill) S. 978, regarding penalties for copyright infringement (entire bill) H.R. 2511, Innovative Design Protection and Piracy Prevention Act (entire bill) S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill) H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill) H.R. 3889, the PARTS Act (entire bill) H.R. 3995, Protecting Consumer Access to Generic Drugs Act (entire bill) H.R. 4216, the Foreign Counterfeit Prevention Act (entire bill) H.R.5326, the Commerce, Justice, Science, and Related Agencies Appropriations Act, (PTO-related Provisions) S. 2323, the Commerce, Justice, Science, and Related Agencies Appropriations Act, (PTO-related Provisions) Issues related to possible trademark law legislation Issues related to possible patent law legislation
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · second_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) FDA user fee programs 16. Specific Lobbying Issues (continued): H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements H.R. 5651, FDA Reform Act (Upton) pharmaceutical, medical device issues S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 2516, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,240,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office
2012 · second_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates [no bill number] Technical changes to America Invents Act [H.R. 1249 and S.23] International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,840,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2012 · second_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) - FDA user fee programs H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements H.R. 5651, FDA Reform Act (Upton) - pharmaceutical, medical device issues S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices S. 2516, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Copyright/Patent/Trademark
HR 3995 - Protect Consumers Access to Generic Drugs Act - provisions related to patent settlements S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements HR 3497 - MODDERN Cures Act of 2011 - provisions related to data protection S 27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics HR 3261 - Stop Online Piracy Act - provisions related to anti-counterfeiting S 373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S 968 - Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to anti-counterfeiting HR 2182,S 1734 - Generating Antibiotic Incentives Now Act of 2011- provisions related to antibiotics and incentives
Client expense: $1,440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Pharmacy
*FEHBP prescription drugs - HR 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. *Pay-for-delay settlements - S 27, Preserve Access to Affordable Generics Act. *Antitrust exemption for independent pharmacies - HR 1946, Preserving Our Hometown Independent Pharmacies Act of 2011. *FDA user fee programs - HR 3988, Generic Drug and Biosimilar User Fee Act of 2012. *Pay-for-delay settlements - HR 3995, Protecting Consumer Access to Generic Drugs Act of 2012. *FDA oversight of medical devices - S 2193, Ensuring Safe Medical Devices for Patients. *Pharmaceutical, medical device issues - HR 5651, Food and Drug Administration Reform Act of 2012; S 2516, Food and Drug Administration Safety and Innovation Act; S 3187, Food and Drug Administration Safety and Innovation Act. *Standards for on-line pharmacies - S 2002, Online Pharmacy Safety Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES
2012 · second_quarter · Copyright/Patent/Trademark
Opposed efforts to preclude settlements in patent litigation. H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012 S. 27, Preserve Access to Affordable Generics Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Pharmacy
FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs H.R.2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R.3839 - Drug Shortage Prevention Act of 2012 H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R.4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 S.44 Medicare Prescription Drug Negotiation Act S.296 and H.R.2245 Preserving Access to Life-Saving Medication Act S.373 Fair Prescription Drug Competition Act S.1584 - Drug Safety and Accountability Act of 2011 S.1734 - Generating Antibiotic Incentives Now Act of 2011 S.2295 - Patient Safety and Generic Labeling Improvement Act S.2516 - Food and Drug Administration Safety and Innovation Act S.3187 Food and Drug Administration Safety and Innovation Act
Client expense: $504,925 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · second_quarter · Copyright/Patent/Trademark
Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs H.R.2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3497 - MODDERN Cures Act of 2011 H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R.4332 - Generic Drug Application Review Fairness Act of 2012 H.R. 5651 - Food and Drug Administration Reform Act of 2012 S.27 Preserve Access to Affordable Generics Act S.373 Fair Prescription Drug Competition Act S.1734 - Generating Antibiotic Incentives Now Act of 2011 S. 1882 - The Fair and Immediate Release of Generic Drugs Act S.2516 - Food and Drug Administration Safety and Innovation Act S.3187 Food and Drug Administration Safety and Innovation Act
Client expense: $504,925 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · second_quarter · Copyright/Patent/Trademark
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: Not reported · Firm income: $29,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) S. Con. Res 50 (Internet governance) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H.R. 6012 (Customs Redaction Bill for Semiconductor Chips) H.R. 6029 (Economic Espionage) H. Con. Res. 42 (The Creativity and Innovation Resolution) H. Con. Res. 127 (Internet Governance)
Client expense: $60,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · first_quarter · Copyright/Patent/Trademark
"S. 27 -- Preserve Access to Affordable Generics Act (entire bill) "H.R. 516 -- Bring Jobs Back to America (Section 7) "H.R. 1056 -- Patent Continuing Disclosure Act (entire bill) "H.R. 2276, study on genetic testing (entire bill) S. 968, PROTECT IP Act (entire bill) H.R.3261, Stop Online Piracy Act (SOPA) S.2029, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill) H.R. 3782, Online Protection and Enforcement of Digital Trade Act (OPEN)(entire bill) S. 978, regarding penalties for copyright infringement (entire bill) S. 623, Sunshine in Litigation Act (entire bill) H.R. 966, Lawsuit Abuse Reduction Act (entire bill) S. 533, Lawsuit Abuse Reduction Act (entire bill) H.R. 2511, Innovative Design Protection and Piracy Prevention Act (entire bill) S. 1228, Combating Military Counterfeits Act of 2011 (entire bill) H.R. 2933, Sound Recording Simplification Act.(entire bill) S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill) H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011 (entire bill) H.R. 3889, the PARTS Act (entire bill) H.R. 3995, Protecting Consumer Access to Generic Drugs Act (entire bill) H.R. 4216, the Foreign Counterfeit Prevention Act (entire bill) Issues related to ICANN and new gltds Issues related to possible trademark law legislation
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · first_quarter · Copyright/Patent/Trademark
Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs H.R.2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3497 - MODDERN Cures Act of 2011 H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R.4332 - Generic Drug Application Review Fairness Act of 2012 S.27 Preserve Access to Affordable Generics Act S.373 Fair Prescription Drug Competition Act S.1734 - Generating Antibiotic Incentives Now Act of 2011 S. 1882 - The Fair and Immediate Release of Generic Drugs Act
Client expense: $480,425 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · first_quarter · Pharmacy
FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, and generic drugs Bills: H.R.2182 Generating Antibiotic Incentives Now Act of 2011 H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 H.R.3839 - Drug Shortage Prevention Act of 2012 H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012 H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012 H.R.4332 - Generic Drug Application Review Fairness Act of 2012 S.44 Medicare Prescription Drug Negotiation Act S.296 and H.R.2245 Preserving Access to Life-Saving Medication Act S.373 Fair Prescription Drug Competition Act S.1584 - Drug Safety and Accountability Act of 2011 S.1734 - Generating Antibiotic Incentives Now Act of 2011
Client expense: $480,425 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2012 · first_quarter · Pharmacy
H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) FDA user fee programs 16. Specific Lobbying Issues (continued): H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices H.R. 3209, Premarket Predictability Act (Shimkus) changes to the device process H.R. 3208, Patients Come First Act (Shimkus) - changes to the device process H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act of 2011 (Paulsen) changes to the device process Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs. 18. Lobbyists (continued): K. Callahan: Ross (March 2005- January 2012); Research Assistant, Senator Tim Johnson (October 2001 March 2005). D. Mott-Bronson: (June 1998 - September 2002); Democratic Professional Staff Member, House International Relations Committee, Representative McKinney (September 2002 December 2002).
Client expense: $2,450,000 · Firm income: Not reported
Government targets: Administration on Aging, Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office
2012 · first_quarter · Pharmacy
*FEHBP prescription drugs - HR 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. *Pay-for-delay settlements - S 27, Preserve Access to Affordable Generics Act. *Antitrust exemption for independent pharmacies - HR 1946, Preserving Our Hometown Independent Pharmacies Act of 2011. *FDA user fee programs - HR 3988, Generic Drug and Biosimilar User Fee Act of 2012. *Pay-for-delay settlements - HR 3995, Protecting Consumer Access to Generic Drugs Act of 2012. *FDA oversight of medical devices - S 2193, Ensuring Safe Medical Devices for Patients.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $5,310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2012 · first_quarter · Pharmacy
H.R. 3995, Protecting Consumer Access to Generic Drugs Act; The Prescription Drug User Fee Act ("PDUFA V"); Prescription Drug Abuse; H.R. 452, Medicare Decisions Accountability Act (repealing provisions of healthcare law relating to the Independent Payment Advisory Board/IPAB); S.1002/H.R. 4223, Safe Doses Act; and Biologics Price Competition Act implementation;
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2012 · first_quarter · Copyright/Patent/Trademark
HR 3995 - Protect Consumers Access to Generic Drugs Act - provisions related to patent settlements S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements HR 3497 - MODDERN Cures Act of 2011 - provisions related to data protection S 27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics HR 3261 - Stop Online Piracy Act - provisions related to anti-counterfeiting S 373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S 968 - Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to anti-counterfeiting HR 2182,S 1734 - Generating Antibiotic Incentives Now Act of 2011- provisions related to antibiotics and incentives
Client expense: $2,120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Pharmacy
S. 1882, the FAIR Generics Act S. 27, the Preserve Access to Affordable Pharmaceuticals Act HR 3995, the Protecting Consumer Access to Generic Drugs Act S. 296, HR 2245, The Preserving Access to Life Savings Medications Act HR 4332, the Generic Drug Application Review Fairness Act HR 3998, Generic Drug and Biosimilar User Fee Act HR 2182, S. 1734, the Generating Antibiotic Incentives Now Act Amending Section 505(j) of the Food, Drug, and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclaims seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications Supreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceuticals Industries, Ltd. Prospective legislation establishing a generic drug user fee program Prospective legislation establishing a biosimilar user fee program Establishment of a federal track and trace system for pharmaceuticals The use of Risk Evaluation Mitigation Strategies (REMS) programs by brand drug companies to delay generic competition International Nonproprietary Names for Biosimilars
Client expense: $200,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Copyright/Patent/Trademark
H.R. 3782, the Online Protection Enforcement of Digital Trade Act H.R. 3261, the Stop Online Piracy Act; H.R. 3995, the Protecting Consumer Access to Generics Act of 2012 S. 968, the Preventing Real Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 S. 1886, the Counterfeit Drug Penalties Act
Client expense: $250,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Federal Deposit Insurance Corporation (FDIC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Legal Services Corporation, Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Trade Representative (USTR), White House Office
2012 · first_quarter · Copyright/Patent/Trademark
Opposed efforts to preclude settlements in patent litigation. H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012 S. 27, Preserve Access to Affordable Generics Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H. Con. Res. 42 (The Creativity and Innovation Resolution)
Client expense: $100,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · first_quarter · Copyright/Patent/Trademark
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: Not reported · Firm income: $15,000
Government targets: SENATE